FDA-cleared profile

syngo.CT LVO Detection

Siemens Medical Solutions USA, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.

Clinical role
Notification-only, parallel worklist-prioritization support with an external alert and no image highlighting; standard-of-care review remains required
Images and patients
CT/CTA · Brain/head vasculature, specifically the ICA, M1, and M2 segments
Key limitation
Keep in mind: Intended for patients aged 22 or older and excludes old infarcts or other diseases affecting brain vasculature, metal artifacts such as coils, and surgical signs. The triage output is informational only, not diagnostic, and does not replace review of the original CTA. Standalone validation covered 602 retrospective cases from four U.S. sites.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain/head vasculature, specifically the ICA, M1, and M2 segments Input: Contrast-enhanced CT angiography images of the head from patients aged 22 or older suspected of stroke-related circulation occlusion; Siemens and other CT vendors are listed, with exclusions for old infarcts or other brain-vascular disease, metal artifacts, and surgical signs.
  • Who uses it?Intended users: Qualified clinicians including radiologists, neuroradiologists, and neurologists; the comparison table also lists clinical administrators
  • What does the software produce?Output: A case-level notification of suspected LVO or processing finished, optionally sent to an external notification device; the output does not highlight any portion of the image and does not alter the original medical image.
  • What is its most important limitation?Key limitation: Intended for patients aged 22 or older and excludes old infarcts or other diseases affecting brain vasculature, metal artifacts such as coils, and surgical signs. The triage output is informational only, not diagnostic, and does not replace review of the original CTA. Standalone validation covered 602 retrospective cases from four U.S. sites.

Clinical takeaway. Clinical role: AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.

Evidence takeaway. Evidence from the reviewed source record: FDA packet: standalone testing used 602 retrospective CT datasets from 602 patients at four U.S. sites, including 307 positive cases with ICA, M1, or M2 occlusions. Two U.S.-board-certified neuroradiologists established ground truth with third-reader adjudication for disagreement. Observed sensitivity was 90.6% and specificity 88.8%; all cases processed in under 110 seconds with a median of 42 seconds.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AI-assisted acute-care triage and notification of suspected large-vessel occlusion on contrast-enhanced head CTA to prioritize review; not diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Notification-only, parallel worklist-prioritization support with an external alert and no image highlighting; standard-of-care review remains required
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Contrast-enhanced CT angiography images of the head from patients aged 22 or older suspected of stroke-related circulation occlusion; Siemens and other CT vendors are listed, with exclusions for old infarcts or other brain-vascular disease, metal artifacts, and surgical signs.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
A case-level notification of suspected LVO or processing finished, optionally sent to an external notification device; the output does not highlight any portion of the image and does not alter the original medical image.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Acute-care stroke and LVO triage workflow
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Qualified clinicians including radiologists, neuroradiologists, and neurologists; the comparison table also lists clinical administrators
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Intended for patients aged 22 or older and excludes old infarcts or other diseases affecting brain vasculature, metal artifacts such as coils, and surgical signs. The triage output is informational only, not diagnostic, and does not replace review of the original CTA. Standalone validation covered 602 retrospective cases from four U.S. sites.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA packet: standalone testing used 602 retrospective CT datasets from 602 patients at four U.S. sites, including 307 positive cases with ICA, M1, or M2 occlusions. Two U.S.-board-certified neuroradiologists established ground truth with third-reader adjudication for disagreement. Observed sensitivity was 90.6% and specificity 88.8%; all cases processed in under 110 seconds with a median of 42 seconds.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet: standalone testing used 602 retrospective CT datasets from 602 patients at four U.S. sites, including 307 positive cases with ICA, M1, or M2 occlusions. Two U.S.-board-certified neuroradiologists established ground truth with third-reader adjudication for disagreement. Observed sensitivity was 90.6% and specificity 88.8%; all cases processed in under 110 seconds with a median of 42 seconds.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
90.6% (95% CI: 86.8%, 93.3%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
88.8% (95% CI: 84.7%, 91.9%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

syngo.CT LVO Detection regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K243145
  • Samplen=602
  • Sites4
  • IndependenceIndependence not established

K243145

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K243145. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Contrast-enhanced CT angiography images of the head from patients aged 22 or older suspected of stroke-related circulation occlusion; Siemens and other CT vendors are listed, with exclusions for old infarcts or other brain-vascular disease, metal artifacts, and surgical signs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K243145: syngo.CT LVO Detection

  2. Routing

    Source context, not route validation: Deployment compatibility is described with the syngo.via platform; DICOM is an applicable software standard and results can be sent to an external notification device. The FDA packet does not establish exact local RIS/PACS interface versions.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K243145: syngo.CT LVO Detection

  3. AI processing

    Source context, not route validation: The exact FDA package describes deployment compatibility of syngo.CT LVO Detection with the syngo.via platform. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Feature syngo.CT LVO Detection syngo.CT Brain Hemorrhage Comparison" … "Deployment Compatibility syngo.via platform syngo.via platform, Similar". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K243145: syngo.CT LVO Detection

  4. Returned objects

    Source context, not route validation: A case-level notification of suspected LVO or processing finished, optionally sent to an external notification device; the output does not highlight any portion of the image and does not alter the original medical image.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K243145: syngo.CT LVO Detection

  5. Viewer/worklist/report

    Unresolved route: A case-level notification of suspected LVO or processing finished, optionally sent to an external notification device; the output does not highlight any portion of the image and does not alter the original medical image.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K243145: syngo.CT LVO Detection

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes deployment compatibility of syngo.CT LVO Detection with the syngo.via platform. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Feature syngo.CT LVO Detection syngo.CT Brain Hemorrhage Comparison" … "Deployment Compatibility syngo.via platform syngo.via platform, Similar". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Deployment compatibility is described with the syngo.via platform; DICOM is an applicable software standard and results can be sent to an external notification device. The FDA packet does not establish exact local RIS/PACS interface versions.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Monitoring
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for syngo.CT LVO Detection; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243145
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Brain/head vasculature, specifically the ICA, M1, and M2 segments
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-04-10
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K243145 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K243145: syngo.CT LVO Detection

    U.S. Food and Drug Administration - Published 2025-04-10 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. syngo.CT LVO Detection model card (K243145)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K243145

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K243145 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251610

qER-CTA (v1.0)

Qure.ai Technologies

Authorized purpose: Parallel notification of suspected anterior-circulation large vessel occlusion on acute head CTA for specialist review; notification only, not diagnosis.

Modality
CT/CTA
Anatomy
Brain anterior circulation: internal carotid artery and M1 segment of the middle cerebral artery
Decision
2025-09-08
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K233968

CINA-iPE

Avicenna.AI

Authorized purpose: Worklist triage and notification for suspected incidental pulmonary embolism on contrast-enhanced CT acquired for another indication; not a diagnostic device

Modality
CT/CTA
Anatomy
Lung and pulmonary arterial segments containing incidental pulmonary embolism; subsegmental arteries are out of scope
Decision
2024-03-13
FDA-cleared K221248

Rapid LVO

iSchemaView Inc.

Authorized purpose: Assist hospital networks and trained radiologists with workflow triage by flagging and communicating suspected ICA or MCA-M1 large-vessel occlusion findings in head CTA images.

Modality
CT/CTA
Anatomy
Head/brain vasculature, specifically the intracranial ICA and MCA-M1 segments.
Decision
2022-05-31

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history